ISB 2001
Alternative Names: ISB-2001; TREAT™ trispecific antibody - Ichnos SciencesLatest Information Update: 11 Jun 2025
At a glance
- Originator Ichnos Sciences
- Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins; Trispecific antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Multiple myeloma
- Preclinical Haematological malignancies
Most Recent Events
- 02 Jun 2025 Ichnos Glenmark Innovation plans a registrational trial in Multiple myeloma
- 02 Jun 2025 Efficacy, safety and pharmacokinetics data from a phase I trial in Multiple myeloma released by Ichnos Glenmark Innovation
- 05 May 2025 ISB 2001 receives Fast Track designation for Multiple myeloma [Parenteral,Injection] (Second-line therapy or greater) in USA